<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01348737</url>
  </required_header>
  <id_info>
    <org_study_id>D4080C00001</org_study_id>
    <secondary_id>2011-001337-16</secondary_id>
    <nct_id>NCT01348737</nct_id>
  </id_info>
  <brief_title>Assessment of Safety, Tolerability and Blood Concentrations of Single Doses of AZD3839 in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel-group Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Biomarkers of AZD3839 Including an Open-label Food Effect Group in Healthy Male and Female Volunteers of Non-childbearing Potential</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety, tolerability and blood concentration of
      AZD3839 following oral administration of single doses in healthy men and women of
      non-childbearing potential
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Event as a measure of safety and tolerability of AZD3839 (Part 1)</measure>
    <time_frame>Part 1 - AEs will be collected from admission to the study centre (Visit 2, Day-1) until the follow-up visit (Visit 3) approximately 15 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Adverse Events as a measure of Safety and tolerability of AZD3839 (Part 2)</measure>
    <time_frame>Part 2 - AEs will be collected from admission to the study centre (Visit 2, Day-1) until the follow-up visit (Visit 4) approximately 20 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time at which maximum concentration occurs in AZD3839 (Part 1)</measure>
    <time_frame>pre-dose, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 56 and 72 hours after the administration of the investigational product, as well as on Day 4 and at the follow-up visit (Visit 3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration of AZD3839 in plasma (Part 1)</measure>
    <time_frame>Part 1 - pre-dose, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 56 and 72 hours after the administration of the investigational product, as well as on Day 4 and at the follow-up visit (Visit 3)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at which maximum concentration occurs in AZD3839 (Part 2)</measure>
    <time_frame>Part 2 - at pre-dose, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 56 and 72 hours after the Administration. May be taken at the follow-up visit (Visit 4)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration of AZD3839 in plasma (Part 2)</measure>
    <time_frame>Part 2 - at pre-dose, 20 and 40 minutes, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 56 and 72 hours after administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Alzheimer's Disease</condition>
  <condition>Safety</condition>
  <condition>Tolerability</condition>
  <condition>Blood Concentration</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>AZD3839</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD3839 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3839</intervention_name>
    <description>Single Oral Dose</description>
    <arm_group_label>AZD3839</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD3839 Placebo</intervention_name>
    <description>Single Oral Dose</description>
    <arm_group_label>AZD3839 Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female volunteers of non-childbearing potential aged 18 to 55 years
             (inclusive) with suitable veins for cannulation or repeated venipuncture

          -  Have a body mass index (BMI) between 19 and 30 kg/m2 (inclusive) and weigh between 50
             kg and 100 kg (inclusive)

          -  Creatinine clearance in the normal range (&gt;80 mL/min estimated according to
             Cockroft-Gault)

          -  Healthy volunteers should have a serum potassium concentration of â‰¥3.8 mmol/L at
             screening (Visit 1) and on admission to the study centre (Day -1)

          -  Clinically normal findings on physical examination in relation to age, as judged by
             the Investigator

        Exclusion Criteria:

          -  History of any clinically significant disease or disorder which, in the opinion of the
             Investigator, may either put the healthy volunteer at risk because of participation in
             the study, or influence the results or the healthy volunteer's ability to participate
             in the study

          -  History of psychotic disorder amongst first degree relatives

          -  Significant orthostatic reaction at enrolment as judged by the Investigator

          -  Prolonged QTcF greater than 450 msec or shortened QTcF less than 340 msec or family
             history of long QT syndrome or sudden death

          -  Healthy volunteer is a vegetarian/lactose intolerant (exclusion criterion only
             applicable for healthy volunteers participating in Part 2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dr Darren Wilbraham, MBBS DCPSA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Drug Research Unit at Guy's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dr Paul Bjornsson</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2011</study_first_submitted>
  <study_first_submitted_qc>May 4, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 5, 2011</study_first_posted>
  <last_update_submitted>April 5, 2012</last_update_submitted>
  <last_update_submitted_qc>April 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>double-blind</keyword>
  <keyword>placebo-controlled</keyword>
  <keyword>AZD3839</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>Alzheimer's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

